G1 Therapeutics Announces Financial Update and Corporate Progress Webcast for First Quarter of 2024

G1 Therapeutics, a commercial-stage oncology biopharmaceutical company, is pleased to announce a webcast and conference call on May 1, 2024, to provide an update on their financials and corporate progress for the first quarter of 2024. The event will commence at 8:30 a.m. ET and can be accessed by registering through the provided link on the company’s website. It is advised to join the call 10 minutes prior to its start time. A live and archived webcast will also be available on the Events & Presentations page of their website for those unable to attend in person.

G1 Therapeutics has a mission to develop next-generation therapies that improve the lives of individuals affected by cancer. Their first commercial product is COSELA® (trilaciclib), which they are currently evaluating for use in combination with cytotoxic therapies or immunotherapy for conditions with high unmet needs such as triple-negative breast cancer and extensive stage small cell lung cancer. The company aims to provide innovative therapeutic solutions for cancer patients, making them an essential resource in the fight against this devastating disease. G1 Therapeutics is headquartered in Research Triangle Park, N.C., and more information about the company can be found on their website at http://www.g1therapeutics.com and their social media platforms like X (formerly known as Twitter) @G1Therapeutics and LinkedIn.

For any further questions or inquiries, please contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com. Trademarks owned by G1 Therapeutics, Inc., include G1 Therapeutics®, COSELA®, and their respective logos.